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ABSTRACT
Objective: Esomeprazole (ESO) is one of the proton-pump inhibitors and is used to treat gastroesophageal reflux. It is sensitive to low pH, heat, 
moisture, and oxidation, which often means that ESO in clinical samples is degraded at the time of storage, affecting analysis results. This study aimed 
to analyze the in vivo stability of ESO in subjects’ plasma samples by testing the incurred sample stability (ISS) of ESO in plasma following 7, 14, and 
28 days of storage at two concentrations close to Cmax and one concentration in the elimination phase.
Methods: Samples were analyzed using high-performance liquid chromatography with a C18 column with detection at 300 nm using a photodiode 
array detector. Lansoprazole was used as an internal standard.
Results: The ESO pharmacokinetics profile in the plasma samples yielded the values of Cmax 704.57–1425.85 ng/mL; tmax is 2.25 h; and AUC0-t is 
2444 ng.h/mL. ISS testing of plasma samples values were 6.50%, 5.73%, and 4.57% on first Cmax concentration; 3.55%, 4.84%, and 3.68% on 2nd Cmax 
concentration; and 4.04%, 4.80%, and 4.98% on elimination phase concentration.
Conclusion: ISS testing results of plasma samples from six healthy subjects who were administered doses of 40 mg of ESO stored for 28 days showed 
that it fulfilled the acceptance criteria (<20%) of the 2011 EMEA Bioanalytical Guidelines with a %diff value in all incurred samples of 6.5%.
Keywords: Esomeprazole, Lansoprazole, Plasma, Incurred sample, High-performance liquid chromatography, Photodiode array.
INTRODUCTION
Esomeprazole (ESO) is a proton-pump inhibitor (PPI) that is suggested 
for the reduction of symptoms in patients with gastroesophageal reflux 
disease [1,2]. ESO as PPI inhibits hydrogen-potassium adenosine 
triphosphatase in gastric parietal cells and thus blocks gastric acid 
secretion [1,2]. ESO is the first single optical isomer PPI, derived from 
omeprazole, which provides better acid control than other racemic PPI 
and has favorable pharmacokinetic profile compared to omeprazole [3].
Method validation includes a long-term stability parameter; however, 
long-term in vitro stability tests do not represent the in vivo stability 
of a drug compound. Therefore, incurred sample stability (ISS) 
testing is required for clinical samples containing the analyte, which 
involves a reanalysis of actual clinical samples over a period of time for 
determining whether the analyte is stable and whether the analytical 
concentration is reproducible [4-6].
ESO has high sensitivity to heat and acidic medium [7,8]; therefore, 
it is formulated in delayed-release tablets and capsules for oral 
administration [8]. The issue of ESO stability should be a concern 
because it is sensitive to acidic pH, heat, and moisture and is also easily 
oxidized [7,9,10], all of which leads to poor long-term storage results 
on samples [7].
ESO is a highly variable drug (HVD), with coefficient of variation (CV)% 
of the pharmacokinetic parameters >30% [11]. The bioequivalence 
study regarding HVDs is schematically recommended using about 30 
subjects to meet the requirements of the European Medicines Agency 
(EMA) and Food and Drug Administration [12]. Therefore, a longer 
time span of bioequivalence study is needed, and the storage time for 
samples is increased as well.
The Global Contract Research Organizations (CROs) Council for 
Bioanalysis recommends that ISS tests should not be routinely 
conducted but rather performed on a case-by-case basis when certain 
analytical stability issues are suspected in incurred samples [13]. Due 
to the known instability of ESO, an ISS analysis was performed using 





Nexium® 40 mg tablet was purchased from PT AstraZeneca Indonesia 
(Jakarta, Indonesia). ESO magnesium trihydrate was purchased 
from Dr. Reddy’s Laboratories Ltd. (Hyderabad, India); lansoprazole, 
which was used as an internal standard, was purchased from Sigma-
Aldrich Pvt. Ltd. (Singapore). The chromatography mobile phases 
contained chromatographic grade methanol, sodium dihydrogen 
phosphate, disodium hydrogen phosphate, and acetonitrile, which were 
purchased from Merck KGaA (Darmstadt, Germany). Reagents such 
as dichloromethane, o-phosphoric acid, and sodium hydroxide were 
obtained from Merck KGaA (Darmstadt, Germany). Aquabidest was 
obtained from PT Ikapharmindo Putramas (Jakarta, Indonesia).
Calibration standards and quality controls (QC)
Stock solutions of ESO and lansoprazole were prepared at concentrations 
of 1.0 mg/mL in methanol. Calibration curves were prepared by 
spiking with an appropriate volume of methanol for producing various 
concentrations of 5, 25, 70, 200, 500, 800, 1200, and 1500 ng/mL. QC 
samples were prepared at low, middle, and high ESO concentrations of 
15, 725, and 1125 ng/mL, respectively.
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Methods
Verification and validation
This study validated a method using high-performance liquid 
chromatography (HPLC) with a photodiode array detector set at a 
wavelength of 300 nm. Separation was conducted on a C18 column 
(Waters, Sunfire™ 5 μm; 250 mm×4.6 mm). The analysis used an isocratic 
separation with acetonitrile-phosphate buffer pH 7.6 (40:60% v/v), a 
column temperature of 40°C, and a flow rate of 1.00 mL/min for 10 min. 
The method had been previously optimized and fully validated in this 
laboratory [14].
Verification and partial validation were performed on the method. 
System suitability tests were conducted using a solution containing 
ESO magnesium trihydrate 50 μg/mL and lansoprazole 50 μg/mL. 
20 µL of the solution was injected onto the column, and the retention 
time, peak area, n value, and tailing factor were determined. Precision 
(CV %) was determined from six repeat injections. Partial validation 
comprised intra-run accuracy, precision, recovery, and the linearity of 
the calibration curve and was determined using the criteria from the 
Bioanalytical guidelines (2011).
Sampling
The test articles used were plasma samples obtained from six selected 
healthy subjects who had been administered 40 mg of ESO magnesium 
(Nexium®). This study was approved by the Medical Research Ethics 
Committee of the Faculty of Medicine, Universitas Indonesia (0036/
UN2.F1/ETIK/2018), and the subjects signed an informed consent 
form before participation. Blood samples were collected 12 times from 
6 healthy subjects 30 min before drug administration (pre-dose) and 
0.5, 1, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, and 10 h following the administration of 
40 mg of ESO magnesium. Blood was collected by a trained phlebotomist 
using Venipuncture Technique and collected in 5 mL anticoagulant 
tubes. The blood collected then was centrifuged to extract the plasma, 
using 11 Rcf for 20 min. The plasma obtained was then transferred to 
a new container.
ESO samples were prepared from the plasma using liquid–liquid 
extraction. A 500 μL aliquot of plasma was placed in a sample tube, and 
25 μL of 50 μg/mL lansoprazole was added. The samples were vortexed 
for 10 s and 5 mL of dichloromethane added before shaking on a vortex 
for 3 min. The sample was then centrifuged at 1149 Rcf for 15 min, and 
4 mL of the supernatant was transferred to a new container.
The supernatant is then evaporated under a stream of nitrogen gas at 
40°C and the residue dissolved in chromatography buffer and shaken 
by vortex for 2 min. After 30 s, 20 μL was analyzed using HPLC.
Pharmacokinetic analysis was performed by calculating the mean Cmax, 
tmax, t1/2, AUC0–t, and AUC0–∞ of the subjects.
ISS testing was performed on subjects’ plasma stored at −80°C on days 
7, 14, and 28 after collection, and samples were processed and analyzed 
as described previously. ISS was analyzed at two concentrations in the 




System suitability tests were conducted for determining the 
reproducibility and suitability of the selected methods. CV% passed the 
required criteria (CV ≤2%) and the results are presented in Table 1 with 
a representative chromatogram in Fig. 1.
Calibration curve linearity
Linearity was r>0.99 and accuracy was (% diff) ±20% for the lower 
limit of quantitation (LLOQ) and ≤±15% for other concentrations. The 
linear equation for the calibration curve was y=0.0018x+0.0017, with 
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area ratio between ESO and the lansoprazole internal standard. The 
calibration curve met the accuracy requirements with % diff ≤ ±20% for 
LLOQ and ≤ ±15% for other concentrations. The results are presented 
in Table 2 and the calibration curve is shown in Fig. 2.
Accuracy, precision, and recovery
Accuracy is a measure of how close the determined concentration of the 
analyte is to the actual concentration in the sample, which is described 
by the parameter %diff. Precision is the relative similarity of repeated 
measurements, which is described by the coefficient of variation (CV%). 
For determining the values of these parameters, plasma ESO was 
analyzed at several concentrations, i.e., LLOQ, QC low, QC medium, and QC 
high, with five replicates at each concentration. Accuracy and precision 
requirements were ≤15% for %diff and CV% in QC samples and ≤20% 
for LLOQ samples. The recovery test was performed by comparing peak 
areas between extracted and unextracted samples. There were no defined 
requirements regarding recovery as long as that the results were precise 
and reproducible. The accuracy and precision results are presented in 
Table 3 and the recovery results are shown in Table 4.
Pharmacokinetic profiles of subjects’ plasma
ESO concentrations were plotted to produce a pharmacokinetic profile 
for each subject to determine their pharmacokinetic parameters, 
namely, the maximum concentration in plasma (Cmax), the maximum 
time (tmax), t1/2, AUC0-t, and AUC0-∞. The values of the determined 
pharmacokinetic parameters for each subject are presented in Table 5, 
with graphs as plotted in Fig. 3.
Table 2: Calibration curve concentrations
Concentration (ng/mL) Area (µV/s) PAR Measurement concentration (ng/mL) %diff
Esomeprazole IS
0.00 0 130422 0.0000 0 0.00
5.00 1582 130394 0.0121 5.83 16.50
20.00 5237 135500 0.0386 20.60 2.99
75.00 16576 132418 0.1252 68.81 −8.26
200.00 45930 132582 0.3464 192.06 −3.97
500.00 124540 133669 0.9317 518.13 3.63
800.00 189132 139330 1.3574 755.31 −5.59
1200.00 315734 134666 2.3446 1305.26 8.77
1500.00 335618 130218 2.5774 1434.94 −4.34
Slope (b) Intercept (a) r R2
0.0018 0.0017 0.9966 0.9931
PAR: Peak area ratio
Fig. 1: Representative chromatogram for system suitability tests
Fig. 2: Calibration curve
Fig. 3: Averaged pharmacokinetic profile of six subjects
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According to the EMEA Bioanalytical Guidelines, 2011, incurred stability 
samples should include two concentrations in the Cmax phase and one 
concentration in the elimination phase in each healthy subjects’ plasma. 
Since tmax varies between subjects, the ISS testing time point also varies. 
In the subject of E1, tmax was at the eighth sampling time and so the ISS 
samples were at the seventh and eighth time points (i.e., at or close to tmax) 
and the 10th time point (i.e., elimination phase). In the subject E4, tmax was 
at the seventh sampling point, so the ISS samples were at the sixth and 
seventh time points (around tmax) and the 10th time point (elimination 
phase). In the remaining subjects, tmax was at the sixth sampling point, so 
the ISS samples were at the fifth, sixth, and ninth time points.
ISS
Testing was performed on the 7th, 14th, and 28th days of plasma storage 
and was counted from the day the pharmacokinetic profiles were 
created. The mean %diff of the ISS tests is shown in Table 6 and the 
concentrations trends in Fig. 4.
CONCLUSION
The pharmacokinetics profiles of ESO in the plasma of six healthy 
subjects exhibited a Cmax range between 704.57 and 1425.85 ng/mL 
with an average of 1174.16 ng/mL and a mean tmax of 2.25 h after a 
single dosage of a 40 mg enteric-coated ESO magnesium tablet. The 
mean AUC0-t was 2444.10 ng.h/mL with the value of AUC0–t/AUC0–∞ 
being 100% in all study subjects.
The ISS of ESO in plasma, therefore, meets the requirements up to 
28 days with the highest %diff from the average ISS sample being 
6.50%.
Table 3: Intraday accuracy and precision
Concentration (ng/mL) ESO IS PAR Measurement concentration (ng/mL) Mean (ng/mL)±SD CV (%) %diff
LLOQ
5.00
3094 237940 0.0130 4.89 4.83±0.07 1.37 −2.30
3290 253662 0.0130 4.85 −2.92
3065 238765 0.0128 4.73 −5.42
3078 236743 0.0130 4.88 −2.33
3109 240726 0.0129 4.80 −3.95
QCL
15.00
5343 230798 0.0232 14.41 14.87±0.40 2.71 −3.95
5370 226480 0.0237 14.93 −0.44
5678 233749 0.0243 15.48 3.19
5340 225369 0.0237 14.92 −0.54
5374 229821 0.0234 14.63 −2.49
QCM
750.00
171112 221656 0.7720 717.19 701.38±22.06 3.15 −4.37
173114 220363 0.7856 729.97 −2.67
166318 222166 0.7486 695.27 −7.30
161112 221656 0.7269 674.85 −10.02
168885 227430 0.7426 689.61 −8.05
QCH
1125.00
269448 230160 1.1707 1091.40 1079.95±16.20 1.50 −2.99
262606 231324 1.1352 1058.11 −5.95
265698 225714 1.1771 1097.45 −2.45
265654 231648 1.1468 1068.97 −4.98
257853 221792 1.1626 1083.79 −3.66
CV: Coefficient of variation, ESO: Esomeprazole, SD: Standard deviation, PAR: Peak area ratio, LLOQ: Lower limit of quantitation, QCL: Quality control low, QCM: Quality 
control medium, QCH: Quality control high
Table 5: Individual subjects’ pharmacokinetic parameters
Subject No. Cmax (ng/mL) tmax (h) t1/2 (h) AUC0–t (ng.h/mL) AUC0–∞ (ng.h/mL) AUC0–t/AUC0‑∞ (%)
E1 1363.34 3 2.93 3616.29 3616.29 100
E2 1131.25 2 1.69 1927.51 1927.51 100
E3 1356.26 2 1.62 2835.11 2835.11 100
E4 1425.85 2.5 1.65 2271.11 2271.11 100
E5 1063.11 2 1.84 2325.35 2325.35 100
E6 704.57 2 1.89 1689.27 1689.27 100
Mean±SD 1174.06±270.92 2.25±0.42 1.94±0.50 2444.10±693.92 2444.10±693.92 100
CV (%) 23.08 18.59 25.73 28.39 28.39
CV: Coefficient of variation, SD: Standard deviation
Table 4: Recovery tests results
Concentration (ng/mL) Extracted area (µV/s) Unextracted area (µV/s) Recovery (%) Mean SD CV (%)
ESO IS ESO IS
QCL
15.00
6598 287347 5643 220798 85.53 86.76 5.72 6.21
6570 305247 5778 223749 87.95
6151 281050 5340 215369 86.82
QCM
750.00
174494 253290 171112 221656 98.06 99.31
173890 261748 173114 220363 99.55
163682 309794 164177 299434 100.30
QCH
1125.00
291768 287908 269448 230160 92.35 90.42
295822 241156 262606 231324 88.77
293824 282644 264853 231854 90.14
CV: Coefficient of variation, ESO: Esomeprazole, SD: Standard deviation, QCL: Quality control low, QCM: Quality control medium, QCH: Quality control high
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Fig. 4: Incurred sample stability trends for each subject














1=1st Cmax concentration; 2=2nd Cmax concentration, 3=Elimination phase 
concentration. ISS: Incurred sample stability 
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